LAG-3-Next Generation Immunotherapy
LAG-3-Next Generation Immunotherapy Market

LAG -3 Next-generation Immunotherapies


The main treatment options in the case of cancer include chemotherapy, radiotherapy, surgery, hormone therapy, stem cell transplant, immunotherapy, Chimeric Antigen Receptor (CAR) T-Cell Therapy, and targeted therapy. These treatments may be used individually or in combination with one another. With the development and approval of these new treatment options, the survival of cancer patients has also improved.


LAG -3 Next-generation Immunotherapies Epidemiological Insights Observed in the 7MM

(2021)


  • The LAG -3 Next-generation Immunotherapies market is expected to grow at a CAGR of 26.3% in the 7MM during the study period of 2019–2035
  • The LAG -3 Next-generation Immunotherapies market is expected to grow at a CAGR of 23% in the US during the study period of 2019–2035
  • The LAG -3 Next-generation Immunotherapies market is expected to grow at a CAGR of 31% in EU5 during the study period of 2019–2035
  • The LAG -3 Next-generation Immunotherapies market is expected to grow at a CAGR of 48% in Japan during the study period of 2019–2035


LAG -3 Next-generation Immunotherapies Market Strengths


The drug pipeline of LAG-3 is robust, with a few major players, and the market of next-generation immunotherapies, specifically the LAG-3 immune checkpoint therapeutics, is not jam-packed. It has become a focus of attention for drug makers because of the relatively large patient population. With these rich and unique emerging pipelines, large-scale companies hold considerable potential to acquire a good market share.


LAG -3 Next-generation Immunotherapies Market Opportunities


Existing knowledge and exposure to the usage of immunotherapy will push the usage of LAG-3 therapies to approval. Usage of immunotherapy can be seen in around 30 different cancer types and this will provide a huge patient pool in terms of opportunities for emerging therapies.


LAG -3 Next-generation Immunotherapies Emerging Drugs


The emerging drugs in the LAG -3 Next-generation Immunotherapies market are

●    Relatlimab (BMS-986016) 

●    Favezelimab (MK-4280) 

●    Tebotelimab (MGD013)

●    Eftilagimod alpha (IMP321)

●    Leramilimab (LAG525)

●    INCAGN02385

●    FS118

●    EMB-02

●    RG6139 (RO7247669)

●    XmAb22841 (XmAb841)

●    Encelimab (TSR-033)

●    Fianlimab (REGN3767)

●    Sym022


LAG -3 Next-generation Immunotherapies Key Players 


The key players working in the LAG -3 Next-generation Immunotherapies market are


  •  Bristol-Myers Squibb
  •  Merck Sharp & Dohme Corp.
  • MacroGenics
  •  Immutep
  • Novartis
  • Incyte Corporation
  • F-star Therapeutics
  • EpimAb Biotherapeutics
  • Roche
  • Xencor
  • AnaptysBio
  • GlaxoSmithKline
  • Regeneron Pharmaceuticals
  • Sanofi
  • Symphogen